Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine by Oh, Yingzi et al.
Clinical applications of patient-speciﬁc induced
pluripotent stem cells in cardiovascular medicine
Yingzi Oh,
1 Heming Wei,
2 Dongrui Ma,
2 Xiaoming Sun,
2 Reginald Liew
1,2
ABSTRACT
The emergence of induced pluripotent stem cell (iPSC)
technology has had a great impact on the ﬁeld of
medicine ever since the ground-breaking discovery in
2006 that overexpression of four speciﬁc transcription
factors was able to turn back the developmental clock of
somatic cells into an embryonic-like state. The resulting
iPSCs carry the developmental potential of human
embryonic stem cells (hESC) without the embryo and
have been heralded as a powerful tool to study
development and disease. This technology has made it
possible for the ﬁrst time for researchers to transform
end-differentiated cells from a particular individual into
another cell type that remains speciﬁc to that individual,
paving the way for novel methods of in vitro disease
modelling and therapeutic applications. This paper
reviews some of the key areas in cardiovascular
medicine in which iPSC technology has been applied and
discusses the future directions and ongoing challenges
ahead in this exciting ﬁeld.
INTRODUCTION
The emergence of induced pluripotent stem cell
(iPSC) technology has had a great impact on the
ﬁeld of medicine ever since ground-breaking work
by Yamanaka and colleagues demonstrated that
the overexpression of four genes (or ‘Yamanaka
factors’: Oct4, Sox2, Klf4, c-Myc) was able to turn
back the developmental clock of somatic cells into
an embryonic-like state.
1 The resulting iPSCs carry
the developmental potential of human embryonic
stem cells (hESC) without the embryo and have
been heralded as a powerful tool to study devel-
opment and disease. The importance of Yamanaka’s
pioneering work is that, for the ﬁrst time,
researchers have a tool to transform end-differen-
tiated cells from a particular individual into another
cell type that remains speciﬁc to that individual
while, at the same time, circumventing many of
the ethical dilemmas that have hampered tradi-
tional embryonic stem cell research to date. The
past few years have witnessed an exponential
increase in the number of publications on iPSCs,
with a number of genetic cardiovascular diseases
being successfully modelled in vitro using this
technology.
23Researchers in this fast-moving ﬁeld
are also moving towards other applications of
iPSCs, including regenerative medicine and drug
testing and discovery.
45There is therefore enor-
mous potential for this new technology, both in
a greater understanding of disease mechanisms and
improved treatments. Moreover, the fact that the
iPSCs are produced from a patient’s own tissue
means that the results of in vitro testing are
directly relevant to that individual, allowing the
new era of ‘personalised medicine’ to become more
of a reality. At this 5-year mark after the initial
iPSC discovery we revisit what has been achieved
to date in relation to cardiovascular medicine,
examine the future directions and critically appraise
the ongoing issues and challenges ahead that
need to be overcome prior to widespread clinical
application.
GENERATION OF PATIENT-SPECIFIC IPSCS AND
CARDIOMYOCYTES
Several methods have been employed to reprog-
ramme somatic cells into iPSCs, which can broadly
be divided into integrating or non-integrating
methods.
3 Integrating methods involve viral
delivery (using retro- or lentiviruses) and integra-
tion of the Yamanaka factors into the host genome
while non-viral non-integrating methods involve
the transient expression of reprogramming factors
(eg, episomal plasmid vectors, minicircle vectors,
RNA and protein delivery) without genomic inte-
gration. In addition, some laboratories have
reported success using viral non-integrating
methods. Methods that involve genomic integra-
tion carry several disadvantages, including random
integration into the host genome resulting in the
expression of endogenous genes and the develop-
ment of a tumorigenic phenotype. This may not be
a major issue if the iPSCs are used for disease
modelling and in vitro testing, but presents a major
barrier to use of these cells as a therapeutic option,
as will be discussed later. Non-integrating methods
are therefore a more suitable option for iPSC-based
therapeutic applications. In our laboratory we have
successfully reprogrammed patients’ dermal ﬁbro-
blasts into iPSCs using both integrating and non-
integrating methods. A schematic diagram of the
stages involved for the generation of patient-
speciﬁc iPSCs and cardiomyocytes from dermal
ﬁbroblasts using the viral integrating method is
shown in ﬁgure 1.
iPSC colonies can be differentiated into func-
tional cardiomyocytes using a variety of methods,
which are very similar to those traditionally
employed to produce cardiomyocytes from hESCs
since both iPSCs and hESCs share very similar
characteristics and differentiation potential.
Currently, the most common method of generating
cardiomyocytes from iPSCs is the embryoid body
(EB) differentiation system which coaxes the iPSCs
to differentiate into the cardiac lineage.
3 Light
microscopic images of iPSC-derived cardiomyocytes
(iPSC-CMs) produced from patient dermal ﬁbro-
blast samples are shown in ﬁgure 2. Although the
iPSC-CMs show many of the functional
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Translational medicinecharacteristics of normal human cardiomyocytes (discussed
below), some other aspects of these cells, including their
morphology, remain relatively immature and ‘fetal-like’, as can
be seen in ﬁgure 2.
FUNCTIONAL CHARACTERISATION OF IPSC-DERIVED
CARDIOMYOCYTES
Before iPSC-CMs can be considered for use as disease models or
in regenerative medicine, the cells produced need to be conﬁrmed
to exhibit the essential functional characteristics of human
cardiomyocytes. The cellular phenotype of iPSC-CMs can be
characterised using several methods including electrophysiolog-
ical and molecular biological techniques. Whole cell patch
clamping can be performed on individual cardiomyocytes after
cells are dissociated from the EBs, allowing for measurement of
speciﬁc ionic currents and action potential (AP) proﬁles. Three
types of AP morphologies can usually be recorded from iPSC-
CMs: ‘atrial-like’, ‘ventricular-like’ and ‘nodal-like’ morphologies
(ﬁgure 3A). In our experience, the majority of cardiomyocytes
produced using viral-based methods of reprogramming
(approximately 65%) exhibit a ventricular-like AP proﬁle. The
iPSC-CMs appear to respond to known drugs affecting the AP in
the expected waydfor example, the AP is prolonged in the
presence of the delayed recitiﬁer potassium current (IKr) blocker
E-4031 (ﬁgure 3C). Electrophysiological properties of the iPSC-
CMs can also be evaluated at the multicellular level using
microelectrode array mapping techniques; areas within EBs
observed to be contracting are dissected and placed on micro-
electrode array plates where ﬁeld potentials and morphologies
across the cells of interest can be recorded. Traditional
methods of assessing intracellular Ca
2+ handling, such as use of
Ca
2+-sensitive ﬂuorescent indicators and confocal microscopy,
can be applied to iPSC-CMs to conﬁrm the presence of intact
and functional Ca
2+ handling apparatus (ﬁgure 3D). Molecular
biological techniques to conﬁrm functionality of the iPSC-CMs
include immunocytochemistry, phosphoproteomic assays and
quantitative reverse transcriptase PCR (qRT-PCR) to identify
molecular targets and expression levels of key proteins found in
normal functional cardiomyocytes.
Figure 1 Schematic diagram showing
the generation of induced pluripotent
stem cell-derived cardiomyocytes
(iPSC-CMs) from human dermal
ﬁbroblasts. Non-embryonic stem cell-
like colonies which appear ﬁrst are not
picked. Only embryonic stem cell-like
colonies which appear later are picked
and maintained. MEF, mouse
embryonic ﬁbroblast; MEA,
microelectrode array.
Figure 2 Light microscopic images of typical dermal ﬁbroblasts, human induced pluripotent stem cells (iPSCs) and iPSC-derived cardiomyocytes
(iPSC-CMs). (A) Parental human dermal ﬁbroblasts (FB) in culture (magniﬁcation 340). (B) Colony of human iPSCs derived from dermal ﬁbroblasts via
retroviral-based reprogramming using Yamanaka factors (magniﬁcation 340). (C) Small cluster of contracting cardiomyocytes (iPSC-CMs) dissociated
from the contracting embryoid bodies derived from iPSCs (magniﬁcation 3200).
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Translational medicineCARDIOVASCULAR DISEASE MODELLING
Advantage of iPSCs over hESCs in disease modelling
Although both hESCs and iPSCs share the pluripotent state and
common utility in disease modelling and therapy, the adult does
not have any hESCs. On the other hand, not only does the
derivation of iPSCs from human somatic cells circumvent the
ethical roadblock associated with the acquisition of hESCs, it is
a procedure which has been achieved by a number of indepen-
dent laboratories, including ours, using a standard and relatively
straightforward protocol. In contrast to hESC-CMs, iPSC-CMs
derived from somatic cells of a particular patient have the
distinct advantage that the cells are individualised, allowing the
study of a genetic disease model that is unique to the patient.
This has paved the way for iPSC-based technology to be used in
human disease modelling, including investigation of rarer
diseases.
6e8
A good starting point to investigate the usefulness of iPSC
technology in modelling human cardiovascular diseases is to
study certain inherited arrhythmogenic diseases caused by rela-
tively simple mutations in which a clear relationship between
genotype and phenotype can be demonstrated. Since the
patient-speciﬁc iPSC-CMs should harbour the same disease-
causing mutation as is present in the host tissue (skin ﬁbroblasts
or hair follicle), researchers could in theory reproduce the clinical
phenotype ‘in the petri dish’ and thus establish an in vitro model
of the disease. A number of pioneering proof-of-concept studies
have been published over the past year in patients with inherited
arrhythmogenic diseases, most notably different subtypes of
long QT syndrome, which conﬁrm that patient-speciﬁc iPSC-
CMs can indeed recapitulate the clinical phenotype in vitro and
thus represent a potential and exciting new method for disease
modelling. These models will allow researchers to better
understand disease mechanisms as well as to investigate the
effects of different compounds on the cellular electrophysiology
of the cells, allowing for novel drug discovery or treatments.
Table 1 summarises the studies in humans to date for which
iPSC technology has been used to generate in vitro models of
a number of cardiovascular diseases.
Modelling the long QT syndrome
Moretti et al were the ﬁrst to show that iPSC-CMs can reca-
pitulate the disease phenotype in humans.
9 They identiﬁed an
autosomal dominant inheritance of a 596G/A missense
mutation in the KCNQ1 gene within a family which has
previously been shown to be associated with long QTsyndrome
type 1 (LQTS1). Electrophysiological parameters in iPSC-CMs
generated from two patients with LQTS1 were compared with
those generated from two unrelated healthy control subjects
using whole-cell patch clamping. AP duration was found to be
signiﬁcantly prolonged and the repolarisation velocity reduced in
LQTS1 iPSC-CMs compared with controls. Furthermore, single
cell electrophysiological analysis showed a reduction speciﬁcally
in the IKS current in ventricular LQTS1 iPSC-CMs compared
with controls with no signiﬁcant differences in the other
currents measured.
Similarly, two other groups reported their ﬁndings on the use
of iPSC-CM disease models for LQTS2. Itzhaki et al obtained
dermal ﬁbroblasts from a patient with LQTS2 harbouring
a known KCNH2 gene mutation (affecting IKr) and showed that
AP duration was prolonged and repolarisation velocity reduced
in LQTS2 iPSC-CMs compared with controls.
10 They measured
and veriﬁed that IKr was signiﬁcantly reduced in LQTS2 iPSC-
CMs. The investigators further tested drugs that could either
relieve or aggravate the clinical phenotype of LQTS2 and found
AP duration to be prolonged with E-4031, which was associated
with new early after depolarisations (EADs) or an increase in the
number or complexity of EADs. The potential therapeutic
effects of nifedipine and the KATP channel opener pinacidil
(which augments the outward potassium current) was tested in
this in vitro model; the drugs were demonstrated to shorten the
AP duration and abolish EADs. Matsa et al also successfully
generated iPSC-CMs from a patient with LQTS2 with a known
KCNH2 mutation and her mother, a carrier for the same
mutation.
11 LQTS2 iPSC-CMs displayed prolonged AP duration
on patch clamp analysis and also prolonged corrected ﬁeld
potential duration (cFPD) on microelectrode array mapping, in
concordance with the results of Itzhaki et al. Similarly, Matsa
et al showed that application of E-4031 prolonged the AP
duration and induced EADs. In addition, they tested the effect of
the KATP channel opener nicorandil and PD-118057, a type 2 IKr
channel enhancer that attenuates channel closing, on LQTS2
iPSC-CMs. Both were able to shorten the AP duration when
used alone or in combination. In addition, nicoranidil was able to
abolish EADs.
Yazawa et al generated iPSC-CMs from two patients with
Timothy syndrome (LQTS type 8) in which a mutation in the
CACNA1C gene which encodes the Cav1.2 channel in humans
leads to a disorder characterised by LQTS, immunodeﬁciency,
Figure 3 Electrophysiological characterisation of human induced
pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). (A) Action
potential traces of three subtypes of human iPSC-CMs determined by
patch clamp. (B) Relative proportion of three subtypes of cardiomyo-
cytes (ventricular CMs (V-CMs), atrial CMs (A-CMs) and nodal-CMs
(N-CMs)) randomly selected from 25 cardiomyocytes differentiated from
a line of iPSCs. (C) Change in action potential (AP) proﬁle in the presence
of 5 mmol of the IKr blocker E-4031. E-4031 increased the AP duration
due to the prolongation of phase 3 of the AP. (D) Ca
2+ transients
recorded from iPSC-CMs using confocal microscopy (top) and Ca
2+
transient proﬁles (bottom).
Heart 2012;98:443e449. doi:10.1136/heartjnl-2011-301317 445
Translational medicinesyndactyly and autism.
12 They analysed time-lapse images of
spontaneously contracting EBs and found that Timothy
syndrome EBs contracted at a slower rate and more irregularly
than control EBs. They also found that the L-type channel
current in iPSC-CMs derived from the patients with Timothy
syndrome had signiﬁcantly reduced voltage-dependent inacti-
vation compared with control cells. Only ventricular-like iPSC-
CMs from patients with Timothy syndrome had APs that were
signiﬁcantly prolonged compared with controls, while atrial and
nodal Timothy syndrome iPSC-CMs did not. This is in contrast
to the study by Moretti et al on LQTS1 iPSC-CMs in which
both ventricular and atrial-like iPSC-CMs displayed the disease
phenotype. In addition, Yazawa et al observed that arrhythmias
and delayed depolarisations were already evident in spontane-
ously beating Timothy syndrome iPSC-CMs while arrhythmias
were only elicited under condition of adrenergic stress with the
application of isoproterenol in LQTS1. Given that Cav1.2 plays
a role in Ca
2+-induced Ca
2+ release from the sarcoplasmic
reticulum, the investigators demonstrated that Cav1.2 inacti-
vation in Timothy syndrome could affect the timing and
amplitude of ventricular Ca
2+ release, leading to larger and more
prolonged Ca
2+ elevations.
Modelling other inherited cardiovascular diseases
In theory, other cardiovascular diseases with a hereditary
component may be modelled using iPSC technology providing
the iPSC-CMs display the key phenotypic features associated
with the disease of interest. However, the process becomes more
complex and difﬁcult with increased heterogeneity of the disease
(both phenotypically and genetically) or with greater involve-
ment of external factors during the natural history of the
disease. LEOPARD syndrome, an autosomal dominant develop-
mental disorder in which the PTPN11 gene encoding a SHP2
phophatase is mutated, and the associated hypertrophic
cardiomyopathy (HCM) phenotype of the disease has been
modelled successfully using iPSC technology.
13 The investigators
found that iPSC-CMs generated from two patients with
LEOPARD syndrome had a larger median surface area, a greater
degree of sarcomeric assembly and a greater degree of NFAT
nuclear localisation than iPSC-CMs from control patients
without disease. Protein molecular targets that could be poten-
tially implicated in the LEOPARD syndrome phenotype were
identiﬁed through proteomic assays, and certain proteins were
found to be more abundant or had increased phosphorylation in
cardiomyocytes derived from the patients with LEOPARD
syndrome compared with control subjects. Our group has
successfully generated iPSC-CMs from a patient with arrhyth-
mogenic right ventricular cardiomyopathy (ARVC) harbouring
a PKP2 mutation and are in the process of modelling the disease
in vitro.
14 However, signiﬁcant hurdles still exist in modelling
the more complex cardiovascular diseases using iPSC technology.
These include: (1) difﬁculty in ensuring a puriﬁed cardiomyocyte
population from iPSCs through standard cardiomyocyte differ-
entiation protocols; (2) the complexities of reproducing
a heterogeneous disease phenotype (eg, ﬁbrofatty change and
increased arrhythmogenicity in ARVC, myoﬁbril disarray in
HCM) which may involve other systemic factors in vitro using
only cardiomyocytes; and (3) limitations of modelling essen-
tially adult-onset diseases (for certain types of cardiomyopa-
thies) using iPSC-CMs with a predominantly fetal-like
phenotype. It is likely that further in vitro manipulation
of iPSC-CMs will be required to model the more complex
diseases successfully. This may involve measures such as over-
expression of apolipoprotein-A1 cDNA or enhancement of the
T
a
b
l
e
1
S
u
m
m
a
r
y
o
f
e
x
i
s
t
i
n
g
s
t
u
d
i
e
s
w
h
i
c
h
h
a
v
e
u
s
e
d
p
a
t
i
e
n
t
-
s
p
e
c
i
ﬁ
c
i
P
S
C
-
C
M
s
i
n
c
a
r
d
i
a
c
d
i
s
e
a
s
e
m
o
d
e
l
l
i
n
g
D
i
s
e
a
s
e
m
o
d
e
l
l
e
d
R
e
p
r
o
g
r
a
m
m
i
n
g
m
e
t
h
o
d
G
e
n
e
m
u
t
a
t
i
o
n
M
e
t
h
o
d
s
u
s
e
d
t
o
e
v
a
l
u
a
t
e
c
e
l
l
u
l
a
r
p
h
e
n
o
t
y
p
e
I
n
v
i
t
r
o
a
b
n
o
r
m
a
l
i
t
y
o
f
p
a
t
i
e
n
t
-
d
e
r
i
v
e
d
i
P
S
C
-
C
M
s
N
u
m
b
e
r
o
f
p
a
t
i
e
n
t
s
i
n
s
t
u
d
y
C
o
n
t
r
o
l
s
u
s
e
d
R
e
f
e
r
e
n
c
e
L
Q
T
S
t
y
p
e
1
R
e
t
r
o
v
i
r
a
l
i
n
t
e
g
r
a
t
i
o
n
R
1
9
0
Q
m
u
t
a
t
i
o
n
i
n
K
C
N
Q
1
g
e
n
e
W
h
o
l
e
c
e
l
l
p
a
t
c
h
c
l
a
m
p
;
i
m
m
u
n
o
h
i
s
t
o
c
h
e
m
i
s
t
r
y
I
K
s
2
(
f
a
t
h
e
r
a
n
d
s
o
n
f
r
o
m
a
f
f
e
c
t
e
d
f
a
m
i
l
y
)
2
h
e
a
l
t
h
y
i
n
d
i
v
i
d
u
a
l
s
9
L
Q
T
S
t
y
p
e
2
R
e
t
r
o
v
i
r
a
l
i
n
t
e
g
r
a
t
i
o
n
A
6
1
4
V
m
u
t
a
t
i
o
n
i
n
t
h
e
K
C
N
H
2
g
e
n
e
W
h
o
l
e
c
e
l
l
p
a
t
c
h
c
l
a
m
p
;
m
u
l
t
i
e
l
e
c
t
r
o
d
e
r
e
c
o
r
d
i
n
g
s
A
P
D
p
r
o
l
o
n
g
a
t
i
o
n
;
d
e
c
r
e
a
s
e
i
n
I
K
r
1
1
h
e
a
l
t
h
y
i
n
d
i
v
i
d
u
a
l
1
0
L
Q
T
S
t
y
p
e
2
L
e
n
t
i
v
i
r
a
l
i
n
t
e
g
r
a
t
i
o
n
G
1
6
8
1
A
m
u
t
a
t
i
o
n
i
n
t
h
e
K
C
N
H
2
g
e
n
e
W
h
o
l
e
c
e
l
l
p
a
t
c
h
c
l
a
m
p
;
m
u
l
t
i
e
l
e
c
t
r
o
d
e
r
e
c
o
r
d
i
n
g
s
;
r
e
s
p
o
n
s
e
t
o
d
r
u
g
s
,
i
n
c
l
u
d
i
n
g
K
+
c
h
a
n
n
e
l
b
l
o
c
k
e
r
s
a
n
d
o
p
e
n
e
r
s
a
n
d
B
-
b
l
o
c
k
e
r
s
A
P
D
p
r
o
l
o
n
g
a
t
i
o
n
;
i
n
c
r
e
a
s
e
d
s
e
n
s
i
t
i
v
i
t
y
o
f
c
e
l
l
s
t
o
d
r
u
g
s
a
n
d
i
n
c
r
e
a
s
e
d
a
f
t
e
r
d
e
p
o
l
a
r
i
s
a
t
i
o
n
s
2
(
m
o
t
h
e
r
a
n
d
d
a
u
g
h
t
e
r
)
C
a
r
d
i
o
m
y
o
c
y
t
e
s
f
r
o
m
H
U
E
S
7
c
e
l
l
l
i
n
e
a
n
d
g
e
n
e
t
i
c
a
l
l
y
u
n
r
e
l
a
t
e
d
h
E
S
C
-
d
e
r
i
v
e
d
ﬁ
b
r
o
b
l
a
s
t
s
1
1
L
Q
T
S
t
y
p
e
8
(
T
i
m
o
t
h
y
s
y
n
d
r
o
m
e
)
R
e
t
r
o
v
i
r
a
l
i
n
t
e
g
r
a
t
i
o
n
G
4
0
6
R
m
u
t
a
t
i
o
n
i
n
t
h
e
C
A
C
N
A
1
C
g
e
n
e
W
h
o
l
e
c
e
l
l
p
a
t
c
h
c
l
a
m
p
;
c
o
n
f
o
c
a
l
m
i
c
r
o
s
c
o
p
y
I
C
a
2
(
u
n
r
e
l
a
t
e
d
)
2
h
e
a
l
t
h
y
i
n
d
i
v
i
d
u
a
l
s
1
2
L
E
O
P
A
R
D
s
y
n
d
r
o
m
e
R
e
t
r
o
v
i
r
a
l
i
n
t
e
g
r
a
t
i
o
n
T
4
6
8
M
m
u
t
a
t
i
o
n
i
n
P
T
P
N
1
1
g
e
n
e
M
i
c
r
o
s
c
o
p
i
c
m
o
r
p
h
o
m
e
t
r
y
;
i
m
m
u
n
o
c
y
t
o
c
h
e
m
i
s
t
r
y
;
a
n
t
i
b
o
d
y
a
r
r
a
y
a
n
d
w
e
s
t
e
r
n
b
l
o
t
a
n
a
l
y
s
e
s
i
P
S
C
-
C
M
s
f
r
o
m
p
a
t
i
e
n
t
s
w
e
r
e
l
a
r
g
e
r
,
s
h
o
w
e
d
h
i
g
h
e
r
d
e
g
r
e
e
o
f
s
a
r
c
o
m
e
r
i
c
o
r
g
a
n
i
s
a
t
i
o
n
a
n
d
p
r
e
f
e
r
e
n
t
i
a
l
n
u
c
l
e
a
r
l
o
c
a
l
i
s
a
t
i
o
n
o
f
N
F
A
T
C
4
2
(
u
n
r
e
l
a
t
e
d
)
2
h
E
S
C
a
n
d
u
n
a
f
f
e
c
t
e
d
b
r
o
t
h
e
r
o
f
o
n
e
o
f
t
h
e
p
a
t
i
e
n
t
s
1
3
A
P
D
,
a
c
t
i
o
n
p
o
t
e
n
t
i
a
l
d
u
r
a
t
i
o
n
;
h
E
S
C
,
h
u
m
a
n
e
m
b
r
y
o
n
i
c
s
t
e
m
c
e
l
l
;
i
P
S
C
-
C
M
,
i
n
d
u
c
e
d
p
l
u
r
i
p
o
t
e
n
t
s
t
e
m
c
e
l
l
-
d
e
r
i
v
e
d
c
a
r
d
i
o
m
y
o
c
y
t
e
s
;
L
Q
T
S
,
l
o
n
g
Q
T
s
y
n
d
r
o
m
e
.
446 Heart 2012;98:443e449. doi:10.1136/heartjnl-2011-301317
Translational medicineWnt/ b-catenin signalling pathway in order to generate a more
mature phenotype.
15 16 Another promising avenue appears to be
in the development of novel methods of engineering cardiac
tissue from iPSC-CMs
17 and assessment of in vitro contrac-
tility.
18 Until such methods are optimised and further research
is performed in the area of maturation of iPSC-CMs, modelling
of the more complex cardiovascular diseases including the
cardiomyopathies will remain a major challenge.
APPLICATIONS IN DRUG TESTING AND DISCOVERY
In vitro drug screening
Part of the process of drug development and testing of new
products for clinical use includes the demonstration that the
product does not have any signiﬁcant cardiac toxicities or
proarrhythmic actions. Early and accurate detection of potential
cardiac toxicities could save the pharmaceutical industry
millions of dollars, avoiding additional funds being wasted to
develop the drug further. There is an increasing demand for good
human models of healthy as well as diseased hearts, given the
limitations of current animal models that are currently used in
drug testing and fundamental differences in cardiac electro-
physiology between animals and humans. Recent studies have
demonstrated that hESC-CMs may represent a novel platform
for electrophysiological drug screening as the cells respond to
a number of cardiac and non-cardiac drugs in the predicted
way.
19 20
Applications in personalised medicine
As demonstrated from the human cardiac disease models
generated so far, several drugs have been tested on patient-
speciﬁc iPSC-CMs and found either to ameliorate or alleviate the
disease phenotype.
9e11 The iPSC-CM disease model allows the
concept of ‘personalised medicine’ to be put forward as these
cells will in theory provide information on the effects of
a particular drug on the individual from which the cells were
obtained. Thus, using this technology, clinicians and scientists
may be able to ascertain the cardiac response or side effects of an
individual to a new drug in vitro before the drug is actually
tested out in the individual. Further work needs to be done
before this application can be realised, including evidence that
the iPSC-CMs generated faithfully reproduce the clinical
phenotype and response to drugs in vitro (in both normal and
diseased individuals) and improved methods of iPSC-CM
generation, since current methods are too laborious and time-
consuming for routine clinical application. However, this
remains an exciting and novel application of iPSC technology
which is not possible with other currently available methods.
Another promising future application of iPSC technology is
the concept of targeted gene modiﬁcation of patient-speciﬁc
iPSCs using homologous recombination techniques and zinc
ﬁnger nucleases (ZFNs) with the exciting prospect of correcting
disease-causing mutations.
21 This strategy has several potential
advantages over conventional gene therapy, including avoidance
of the need for immunosuppression and elimination of the risk of
insertional mutagenesis caused by therapeutic vectors. The
technique has recently been successfully applied in iPSCs to
correct the genetic mutations responsible for a1-antitrypsin
deﬁciency
22 and sickle cell anaemia,
23 although it is still currently
in its infancy and thus remains challenging and inefﬁcient.
Applications in regenerative medicine
Myocardial repair
To date, a wide variety of different stem cell types have been
investigated for their ability to repair the infarcted heart in both
animal studies and human clinical trials.
24 The emergence of
iPSC technology adds an additional cell source that may have
a potential clinical application in this area, although research in
regenerative medicine using these cells is still at an early stage.
25
The major advantage of iPSCs over other cell types for cell
transplantation is the fact that these cells are patient-speciﬁc,
thereby circumventing the important issue of tissue rejection
associated with transplantation procedures. However, enthu-
siasm for use of iPSC technology in regenerative medicine has
been hampered by the increasingly recognised problems of the
unpredictable nature and behaviour of transplanted iPSCs and
the potential for these cells to cause harm.
26 Additional issues
such as the potential teratogenicity of undifferentiated cells and
proarrhythmia of iPSC-CMs need to be addressed before clinical
grade iPSCs can be used in regenerative medicine.
To date, several disease models such as sickle cell anaemia,
27
Parkinson’s disease
28 and haemophilia A
29 have been successfully
treated using iPSC-based therapy. In relation to cardiovascular
medicine, Nelson et al showed that intramyocardial delivery of
iPSCs into the infarcted hearts of mice following ligation of the
left anterior descending artery yielded progeny that properly
engrafted without disrupting cytoarchitecture.
30 Furthermore,
the investigators found that iPSC treatment restored contractile
performance, ventricular wall thickness and electrical stability,
while also achieving in situ regeneration of cardiac, smooth
muscle and endothelial tissue. In another proof-of-concept
study, Mauritz et al showed that injection of iPSC-derived fetal
liver kinase-1 (Flk-1) positive progenitor cells into the ischaemic
myocardium of left anterior descending artery-ligated mice
improved cardiac function following myocardial infarction and
that the Flk-1 positive cells differentiated into cardiovascular
lineages in vitro and in vivo.
31
Biological pacemakers
Another potential and exciting application of iPSC technology in
cardiovascular medicine is in the development of cell-based
therapies for biological pacing. The advent of electronic pace-
makers has transformed the treatment and lives of many
patients suffering from symptomatic bradyarrhythmias over the
past few decades. However, a number of important limitations
still exist with permanent pacemakers, including the need for
a surgical procedure and its associated risks, the ongoing risk of
infection and the need for frequent generator changes and
possible lead changes over the lifetime of the individual (this
becomes more of an issue the younger the patient is at ﬁrst
implant). The concept of a ‘biological pacemaker’ which can
integrate with the host cardiac tissue, generate the electrical
impulses required by the individual (whose intrinsic pacemaker
function is defective/inadequate) and physiologically adapt to
the cardiac requirements of that individual is certainly an
attractive one. One of the ﬁrst major reports on the use of stem
cells for biological pacing involved the implantation of cardio-
myocytes derived from hESCs into the ventricles of pigs with
complete heart block.
32 The investigators performed histological
examination and detailed 3D-electroanatomical mapping to
show that the hESC-CMs integrated with the host cardiac
tissue and were able to pace the swine hearts at a higher rate
than the back-up rate set by the electronic pacemaker. Similar
ﬁndings were obtained by another group using genetically
engineered hESCs transplanted into guinea pig hearts.
33 This
approach, however, requires immunosuppression if applied to
humans since the hESCs are not obtained from the host. The use
of patient-speciﬁc iPSC-CMs may overcome this problem,
although other potential issues regarding tumorigenicity,
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tissue and methods of cell delivery remain.
Ongoing challenges for use of iPSC technology in regenerative
medicine
Despite the encouraging results from preclinical studies,
a number of obstacles still need to be overcome before iPSC-
based therapy can be applied to humans for therapeutic
purposes. One of the most important of these is the potential
of transplanted undifferentiated iPSCs to form teratomas.
Consequently, undifferentiated cells should be removed from
the grafts prior to transplantation. This may be achieved by
manual dissection of areas of beating cardiomyocytes or by
using ﬂuorescence-activated cell sorting with speciﬁc dyes to
select out a high purity of cardiomyocytes.
34 35 Other ways to
circumvent this issue may involve the generation of partially
induced pluripotent stem cells, which do not appear to form
tumours in vivo and can also engraft into the heart,
36 or direct
reprogramming of ﬁbroblasts into differentiated cardiomyocytes
without involving a pluripotent intermediate.
37 38 Using state-
of-the-art genomic technologies, several investigators have
recently provided evidence that in vitro reprogramming and
expansion of iPSCs can result in a number of genetic and epige-
netic abnormalities.
26 These include an increase in the number
of copy number variations which are not found in cells of origin,
deletion or point mutations and abnormalities in DNA meth-
ylation status. A greater understanding of these cells and
the effects of reprogramming is therefore required before clinical
application in regenerative medicine. Another safety concern
in relation to the use of stem cells pertains to the potential
proarrhythmic effects of transplanted stem cells in the
host heart.
39 40 Other issues include the need to generate and
select out large quantities of high purity cardiomyocytes,
safe and effective methods of cell delivery and ensuring that
transplanted cells remain in the myocardium. Novel trans-
plantation technologies such as cardiospheres (cardiac cell
aggregates)
41 and cardiac cell sheets using temperature-respon-
sive culture surfaces may provide solutions to some of these
issues.
42
CONCLUSIONS
Differentiation of human iPSCs in vitro into functional cardio-
myocytes is now becoming a process which can be effectively
manipulated and directed. New and improved protocols for
cardiomyocyte differentiation of iPSCs are rapidly accumulating
in the literature.
43 44 Generation of other cell types related to the
heart and cardiovascular system using iPSC technology is still in
its infancy, although preclinical proof-of-concept studies have
shown some potential for the use of such cells in the treatment
of peripheral vascular disease
45 and valvular heart diseases.
46
Table 2 summarises the current and future applications of iPSC
technology in relation to cardiovascular medicine and the
ongoing challenges ahead. In the immediate future the most
promising application of iPSCs in cardiovascular medicine is in
the areas of disease modelling and in vitro drug testing.
However, an important issue for researchers to address is in
designing strategies that will allow iPSC-CMs to become more
mature in vitro and thus more applicable to human disease
modelling. Other challenges, particularly in relation to the
potential use of iPSCs in regenerative medicine, include the
issues of teratogenicity and potential proarrhythmias. In addi-
tion, current methods of iPSC reprogramming and differentia-
tion into functional cardiomyocytes are still relatively slow,
labour intensive and inefﬁcient. In our laboratory, for example, it
still takes approximately 2e4 months to transform somatic
human cells into iPSC-CMs and requires dedicated personnel to
work manually on the cell lines. Consequently, use of iPSC
technology in most specialised research laboratories around the
world is still currently in the realms of academic research and
discovery. However, improved and faster techniques for gener-
ating human iPSC lines are constantly emerging, such as the
positive selection of cells expressing speciﬁc pluripotency
markers
47 and the use of newer small molecules.
48 In parallel
with these advances, involvement of industry collaborators is
also increasing, making commercial and large-scale production of
human iPSC-CMs that can be used clinically for drug testing
and therapeutics a fast-approaching reality.
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Table 2 Summary of current and future applications of iPSC technology in relation to cardiovascular medicine and ongoing challenges ahead
Cardiovascular application Advantage of using iPSC-technology Ongoing challenges
Disease modelling
< Inherited arrhythmogenic diseases
< Inherited cardiomyopathies
< iPSC-CMs carry same genetic
mutation allowing rarer genetic
diseases to be modelled
< Relatively immature phenotype
< Difﬁculties in modelling more complex
multifactorial diseases
Drug testing and discovery
< Testing of existing drugs on human
cardiomyocytes
< Testing of new drugs
< Unlimited source of human
cardiomyocytes
< Relatively immature phenotype
< Need to improve efﬁciency of iPSC-CM
production and upscaling of cells
Personalised medicine
< In vitro drug testing
< Correction of genetic mutation
< Patient-speciﬁc iPSC-CMs: in vitro
data may be directly relevant to
individual
< Possibility of correcting genetic
mutation speciﬁc to that individual
< Need to demonstrate good correlation
between in vitro data and signiﬁcance
to individual
< Current methods of reprogramming too
slow and inefﬁcient
Regenerative medicine
< Cell transplantation in heart failure/
post myocardial infarction
< Biological pacemakers
< Artiﬁcial heart valves
< Vascular endothelial cells for
peripheral vascular disease
< No need for immunosuppression
< iPSC-CMs can be produced from
patients’ own somatic cells
< Potential teratoma formation of
undifferentiated iPSCs
< Potential proarrhythmias
< Functional and electrical integration
of cells
< Need for puriﬁcation and upscaling
of iPSC-CMs
< Optimal delivery methods
iPSC-CM, induced pluripotent stem cell-derived cardiomyocytes.
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